GOVX B21

Drug Profile

GOVX B21

Alternative Names: DNA G/MVA adjuvanted vaccine; DNA-G/MVA; GM CSF adjuvanted pGA2/JS7 + MVA/HIV62

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator GeoVax Labs; National Institutes of Health (USA)
  • Developer GeoVax Labs
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 20 Oct 2016 Immunogenicity data from a phase I trial in HIV-1 infections released by GeoVax
  • 27 Apr 2015 Discontinued - Phase-I for HIV-1 infections (Prevention) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top